Lopes, G. Et Al. 2018. Phase 3 KEYNOTE-042 Study: Pembrolizumab vs Platinum-Based Chemotherapy as 1l Therapy for Advanced NSCLC with a PD-L1 TPS >= 1%. JOURNAL OF THORACIC ONCOLOGY , vol.13, no.9 .

Lopes, G., Wu, Y., Kudaba, I., Kowalski, D., Cho, B., Turna, H., ... De Castro, G.(2018). Phase 3 KEYNOTE-042 Study: Pembrolizumab vs Platinum-Based Chemotherapy as 1l Therapy for Advanced NSCLC with a PD-L1 TPS >= 1%. JOURNAL OF THORACIC ONCOLOGY , vol.13, no.9.

Lopes, G. Et Al. "Phase 3 KEYNOTE-042 Study: Pembrolizumab vs Platinum-Based Chemotherapy as 1l Therapy for Advanced NSCLC with a PD-L1 TPS >= 1%," JOURNAL OF THORACIC ONCOLOGY , vol.13, no.9, 2018

Lopes, G. Et Al. "Phase 3 KEYNOTE-042 Study: Pembrolizumab vs Platinum-Based Chemotherapy as 1l Therapy for Advanced NSCLC with a PD-L1 TPS >= 1%." JOURNAL OF THORACIC ONCOLOGY , vol.13, no.9, 2018

Lopes, G. Et Al. (2018) . "Phase 3 KEYNOTE-042 Study: Pembrolizumab vs Platinum-Based Chemotherapy as 1l Therapy for Advanced NSCLC with a PD-L1 TPS >= 1%." JOURNAL OF THORACIC ONCOLOGY , vol.13, no.9.

@article{article, author={G. Lopes Et Al. }, title={Phase 3 KEYNOTE-042 Study: Pembrolizumab vs Platinum-Based Chemotherapy as 1l Therapy for Advanced NSCLC with a PD-L1 TPS >= 1%}, journal={JOURNAL OF THORACIC ONCOLOGY}, year=2018}